Virtual Library
Start Your Search
B. Oz
Author of
-
+
P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.04-013 - Clinicopathological Data's of Advanced NSCLC Patients with ROS1 Gene Rearrangement and of Clinical Responses to Crizotinib in TURKEY (ID 1214)
09:30 - 09:30 | Author(s): B. Oz
- Abstract
Background:
The ROS1 oncogene encodes an orphan receptor tyrosine kinase related to anaplastic lymphoma kinase (ALK), leukocyte receptor tyrosine kinase, and members of the insulin receptor family. Chromosomal rearrangement of ROS1 occurs in a variety of human cancers, including non-small cell lung cancer (NSCLC). Crizotinib (XALKORI®) is , first-in-class, small molecule tyrosine kinase inhibitor of ALK, ROS1, and c-MET. It has been approved in several countries for the treatment of advanced ALK-positive NSCLC. A global phase I study of crizotinib includes expansion cohorts for patients with molecularly defined tumors, including a cohort of patients with advanced NSCLC harboring ROS1 fusions.
Methods:
Between January 2014 and January 2015, a total of 542 patients with advanced NSCLC was enrolled. They were all negative for EGFR mutation and also ALK rearrangement. All of the cases of ROS1 rearrangement were identified through a break-apart ROS1 fluorescence in-situ hybridization (FISH) assay together with immunohistocemical ROS1 (D4D6 clone) positivity. Treatment All patients received at least one prior line of standard therapy for advanced NSCLC. After that Crizotinib was administered orally at the standard dose of 250 mg twice daily in continuous 28-day cycles.
Results:
ROS1 rearrangements were found in 5 cases of 542 lung cancer samples, the total incidence was 0,9%. All the tumors of the positive cases were adenocarcinoma. The ROS-1 rearrangements were more frequent in female patients (80%) than male ones. They were all young patients median age 39 years old. The majority of patients had never smoked (60%) and the others were light-smoker. The first patient has been receiving Crizotinib therapy for thirteen months and all patients are still alive. Two patients (40%) achieved a complete response, 2 patients (40%) achieved a partial response. Last patient was started Crizotinib therapy in the March of 2015.
Conclusion:
Patients with ROS1-positive NSCLC have similar demographic characteristics to those with ALK-positive NSCLC. ROS1 rearrangement test is recommended for all patients whose tumors were negative EGFR and ALK. ROS1 rearrangement defines a second molecular subset of NSCLC for which crizotinib is a highly active treatment. This is the first report presenting clinico-pathological data of the patients harboring ROS1 rearrangement in TURKEY.
